ACET Earnings — Adicet Bio, Inc. Common Stock Post-ER Performance | BigEarnings
ACET — Adicet Bio, Inc. Common Stock
XNAS
Price$9.31
Market Cap$87.0M
P/E—
52W Range$6.01 – $17.44
Next Earnings2026-08-06
About Adicet Bio, Inc. Common Stock
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
